Figure 1: Repeated morphine treatment increases microglial Panx1 expression and activity. Figure 3: Genetic ablation of microglial Panx1 prevents naloxone-induced synaptic facilitation in spinal ...
Why is it important to know the proportion of microglia in astroglial cultures and to keep this proportion as low as possible? First, because astrocytes and microglia are very different types of cells ...
Researchers analyzed thousands of microglia from different brain regions of deceased patients who had been diagnosed with a variety of neuropsychiatric and neurodegenerative disorders. Their results ...
In a recent study published in Cell, researchers examined 152,459 microglial transcriptomes from 443 individuals, identifying 12 transcriptional states and their relationship to Alzheimer's disease ...
Recent studies have shown variation in the gene-expression profile and phenotype of microglia across brain regions and between different age and disease states. But the molecular mechanisms that ...
A new imaging technique has shown that microglia in the eye become more active in people with diabetes, signaling damage ...
Microglia normally gobble up and break down Aβ. However, in Alzheimer’s disease, an altered inflammatory state causes them to stop clearing the aggregated peptide. How does this happen, and can it be ...
Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...
Apigenin and Luteolin Modulate Microglial Activation Via Inhibition of STAT1-Induced CD40 Expression
Background. It is well known that most neurodegenerative diseases are associated with microglia-mediated inflammation. Our previous research demonstrates that the CD40 signaling is critically involved ...
Following more than seven years of research, researchers at the University of Seville-IBiS (Institute of Biomedicine of Seville) have identified a new key cell type with a critical role in the ...
ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease –– ARV-102 demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback